Overview
International law firm McDermott Will & Emery is pleased to appoint two new leaders to serve alongside Doug Carsten as co-heads of the global Life Sciences Industry Group. McDermott life sciences lawyers counsel clients worldwide at all stages of development, with demonstrated success across intellectual property, regulatory, transactional, employment, tax and litigation law. The group is composed of lawyers in offices across North America and Europe who work with most of the world’s top 20 biopharma and medical technology companies.
The leadership group now consists of:
- Douglas “Doug” H. Carsten, co-head of McDermott’s global life sciences industry practice
Doug focuses his practice on complex patent litigation disputes and counsels clients across various industries, including pharmaceuticals, biologics, medical devices and diagnostic products. He has substantial first-chair trial experience that includes litigating high-profile and billion-dollar patent cases.
- Emmanuelle Trombe, Paris, co-head of McDermott’s global life sciences industry practice
Emmanuelle represents pharmaceutical, medical device and bio-pharmaceutical companies globally in transactional matters in relation to M&A and divestitures, joint ventures and strategic partnerships, large-scale projects, outsourcing projects, product development, licensing agreements and regulatory matters. She also advises venture capital funds and biopharmaceutical companies in connection with a broad range of financing activities.
- James “Jamie” Ravitz, Washington, DC, co-head of McDermott’s global life sciences industry practice and head of McDermott’s FDA practice
Jamie works alongside clients across the entire spectrum of life sciences and healthcare law, including regulatory counsel, compliance, and investigations and government enforcement. He is particularly focused on Food and Drug Administration (FDA) regulatory counseling and works in partnership with companies and investors across the complete ecosystem of FDA-regulated products – drugs, devices, health technologies, biologics, food, cosmetics and cannabis – to help them achieve their business goals.
“Doug, Emmanuelle and Jamie make a powerhouse leadership trio, and together they provide best-in-class knowledge and counsel across three of the key pillars of our global life sciences capabilities – IP, transactions and regulatory,” said Jerry Sokol, global head of the healthcare practice. “We’ve built a group uniquely designed to service companies at the forefront of biotech, pharmaceuticals, medical devices, diagnostics and digital health, and Emmanuelle’s European focus further increases our representation in key markets for the life sciences industry.”
McDermott’s global Life Sciences Group operates as a cross-border, interdisciplinary team, drawing upon lawyers from the top-ranked healthcare law practice to work at the juncture of health, technology and life sciences. Among the team’s recent notable work, after three years of hard-fought litigation over foundational cancer testing patents, McDermott secured back-to-back wins on behalf of Natera, a global leader in cell-free DNA testing. A Delaware jury awarded the company $19.35 million. The team has also represented an array of clients globally with respect to FDA regulatory due diligence in the context of a variety of cross-border transactions, including Life Science Outsourcing’s acquisition of J-Pac Medical.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
